

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BÜRGER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP05/01077

FILED: FEBRUARY 3, 2005

U.S. APPLICATION NO: 10/597,287

35 USC §371 DATE: JUNE 19, 2008

FOR: SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO]PHENYL]-BENZAMIDE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP05/01077, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "George R. Dohmann", written over a horizontal line.

George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: